Фармакологические аспекты лечения острой гликозидной интоксикации
https://doi.org/10.20340/vmi-rvz.2021.4.CLIN.1
Аннотация
Несмотря на активное внедрение хирургических методов лечения сердечной патологии и новых синтетических кардиотонических средств, сердечные гликозиды (СГ) остаются важной составляющей фармакологической терапии заболеваний сердца. Более того, интерес к данной группе препаратов только возрастает с учетом открытия новых фармакологических эффектов, таких как противоопухолевый и противовирусный. Однако, несмотря на многолетний опыт применения, вопрос ведения пациентов с симптомами как острой, так и хронической интоксикации СГ остается одним из ведущих. В обзоре литературы приводится краткий исторический очерк отравлений сердечными гликозидами, описываются особенности фармакокинетики и фармакодинамики данной группы препаратов. Рассмотрена клиническая картина отравлений СГ. Проанализированы современные представления и ограничения антидотной терапии, а также особенности патогенетического и симптоматического лечения пациентов с острой гликозидной интоксикацией.
Об авторах
М. И. Шперлинг
Военно-медицинская академия им. С.М. Кирова
Россия
Россия
Шперлинг Максим Игоревич, клинический ординатор, Первая кафедра и клиника (терапии усовершенствования врачей) имени академика Н.С. Молчанова
Санкт-Петербург
Е. Г. Кручинин
Государственный научно-исследовательский испытательный институт военной медицины
Россия
Россия
Кручинин Евгений Геннадьевич, кандидат медицинских наук, заместитель начальника отдела
Санкт-Петербург
А. С. Гоголевский
Государственный научно-исследовательский испытательный институт военной медицины
Россия
Россия
Гоголевский Александр Сергеевич, доктор медицинских наук, начальник Центра
Санкт-Петербург
Список литературы
1. Withering W. An account on the foxglove, and some of its medical uses with practical remark on dropsy and other diseases. G. G. J. & J. Robinson, London.1785:207. https://doi.org/10.5962/bhl.title.3869
2. Calderón-Montaño J.M., Burgos-Morón E., Orta M.L., Maldonado-Navas D., García-Domínguez I., López-Lázaro M. Evaluating the cancer therapeutic potential of cardiac glycosides. Biomed. Res. Int. 2014:794930. https://doi.org/10.1155/2014/793930
3. Amarelle L, Lecuona E. The Antiviral Effects of Na,K-ATPase Inhibition: A Minireview. Int J Mol Sci. 2018;19 (8):2154. https://doi.org/10.3390/ijms19082154
4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27): 2129–2200. https://doi.org/10.1093/eurheartj/ehw128
5. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, European Heart Journal. 2016;37(38):2893-2962. https://doi.org/10.1093/eurheartj/ehw210
6. Suvorov A.V., Kaurov Ya.V., Suvorov M.A. Features of cardiac arrhythmias and conduction in acute poisoning with cardiotoxic substances. Bulletin of RUDN university, Medicine. 2014;(3):26-30 (in Russ).
7. Supervia Caparros A., Salgado Garcia E., Calpe Perarnau X., Galicia Paredes M., Garcia Gibert L., Cordoba Ruiz F., Clemente Rodríguez C., Nogué Xarau S. Immediate and 30 days mortality in digoxin poisoning cases attended in the Hospital Emergency Services of Catalonia, Spain. Emergencias Rev la Soc Esp Med Emergencias. 2019;31(1):39-42.
8. Gaillard Y., Krishnamoorthy A., Bevalot F. Cerebra odollam: a `suicide tree’ and cause of death in the state of Kerala. J Ethnopharmacol. 2004;95(2-3):123–126. https://doi.org/10.1016/j.jep.2004.08.004
9. Eddleston M, Ariaratnam C.A., Meyer W.P., Perera G., Kularatne A.M., Attapattu S., Sheriff M.H., Warrell D.A. Epidemic of self-poisoning with seeds of the yellow oleander tree (Thevetia peruviana) in northern Sri Lanka. Trop Med Int Health. 1999;4(4):266-273. https://doi.org/10.1046/j.1365-3156.1999.00397.x
10. Burchell H.B. Digitalis poisoning: historical and forensic aspects. J Am Coll Cardiol. 1983;1(1):506-516. https://doi.org/10.1016/s0735-1097(83)80080-1
11. Gosudarstvennyj reestr lekarstvennyh sredstv. URL: https://grls.rosminzdrav.ru (in Russ).
12. Kanji S., MacLean R.D. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. https://doi.org/10.1016/j.ccc.2012.07.005
13. Morsy N. Cardiac Glycosides in Medicinal Plants. Aromatic and Medicinal Plants – Back to Nature. 2017;(2):29-45. https://doi.org/10.5772/65963
14. Schonfeld W., Weiland J., Lindig C., Masnyk M., Kabat M.M., Kurek A., Wicha J., Repke K.R.H. The lead structure in cardiac glycosides is 5β,14β-androstane-3β14-diol. Naunyn Schmiedebergs Arch. Pharmacol. 1985;329:414-426. https://doi.org/10.1007/BF00496377
15. Brown L., Thomas R., Watson T. Cardiac glycosides with non-rotting steroid to sugar linkages: tools for the study of digitalis structure-activity relationships. Arch. Pharmacol. 1986;332(1):98-102. https://doi.org/10.1007/bf00633205
16. Sousa L.Q., Machado K.D., Oliveira S.F., et al. Bufadienolides from amphibians: A promising source of anticancer prototypes for radical innovation, apoptosis triggering and Na+/K+-ATPase inhibition. Toxicon. 2017;127:63-76. https://doi.org/10.1016/j.toxicon.2017.01.004
17. Ogawa H., Shinoda T., Cornelius F., Toyoshima C. Crystal structure of the sodium-potassium pump (Na+,K+- ATPase) with bound potassium and ouabain. Proc Natl Acad Sci USA. 2009;106(33):13742-13747. https://doi.org/10.1073/pnas.0907054106
18. FDA Approved Drug Products: Lanoxin (digoxin) oral tablets, 2015 (revised in 2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020405s015lbl.pdf
19. Dipolo R., Beaugé L. Sodium/calcium exchanger: Influence of metabolic regulation on ion carrier interactions. Physiological Reviews journal. 2006;86(1):155-203. https://doi.org/10.1152/physrev.00018.2005
20. Schoner W., Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs. 2007;7(3):173-189. https://doi.org/10.2165/00129784-200707030-00004
21. Gonano L.A., Sepúlveda M., Rico Y., Kaetzel M., Valverde C.A., Dedman J., Mattiazzi A., Vila Petroff M. Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias. Circ Arrhythm Electrophysiol. 2011;4(6):947-957. https://doi.org/10.1161/CIRCEP.111.964908
22. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245(1):C1-C14. https://doi.org/10.1152/ajpcell.1983.245.1.C1
23. Yuan Z., Cai T., Tian J., Ivanov A.V., Giovannucci D.R., Xie Z. Na/K-ATPase tethers phospholipase C and IP3 receptor into a calcium-regulatory complex. Mol Biol Cell. 2005;16(9):4034-4045. https://doi.org/10.1091/mbc.e05-04-0295
24. Kamp T.J., Hell J.W. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res. 2000;87(12):1095-1102. https://doi.org/10.1161/01.res.87.12.1095
25. Kushakovskij M.S., Grishkin Yu.N. Arrhythmias of the heart. Heart rhythm and conduction disorder: a guide for doctors. 4th edition. St. Petersburg: Foliant, 2017:720. (in Russ).
26. Levi A.J., Dalton G.R., Hancox J.C., Mitcheson J.S., Issberner J., Bates J.A. Evans S.J., Howarth F.C., Hobai I.A., Jones J.V. Role of intracellular sodium overload in the genesis of cardiac arrhythmias. J Cardiovasc Electrophysiol. 1997;8(6):700–721. https://doi.org/10.1111/j.1540-8167.1997.tb01834.x
27. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-878. https://doi.org/10.1001/jama.289.7.871
28. Bismuth C., Gaultier M., Conso F., Efthymiou M.L. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-162. https://doi.org/10.3109/15563657308990513
29. Bagrov A.Y., Shapiro J.I., Fedorova O.V. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacological reviews. 2009;61(1):9-38. https://doi.org/10.1124/pr.108.000711
30. Yang E.H., Shah S., Criley J.M. Digitalis toxicity: a fading but crucial complication to recognize. Am J Med. 2012;125(4):337-343. https://doi.org/10.1016/j.amjmed.2011.09.019
31. Ito S., Woodland C., Harper P.A., Koren G. P-glycoprotein–mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci. 1993;53(2):PL25–PL31. https://doi.org/10.1016/0024-3205(93)90667-R
32. Hanke N., Frechen S., Moj D., Britz H., Eissing T., Wendl T., Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT Pharmacometrics Syst Pharmacol. 2018;7(10):647-659. https://doi.org/10.1002/psp4.12343
33. Roberts D.M., Buckley N.A. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet. 2007;46(11):897-939. https://doi.org/10.2165/00003088-200746110-00001
34. Chan B.S., Buckley N.A. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014;52(8):824-836. https://doi.org/10.3109/15563650.2014.943907
35. Vodoevich V.P., Maksimov A.I., Pashkovskij A.R., Snitko V.N. Two cases of complete drug-induced atrioventricular block. Medical business: scientific and practical therapeutic journal. 2017;3(55):68-70 (in Russ).
36. Bandara V., Weinstein S. A., White J., Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon. 2010;56(3):273-281. https://doi.org/10.1016/j.toxicon.2010.03.026
37. Roberts D.M., Gallapatthy G., Dunuwille A., Chan B.S. Pharmacological treatment of cardiac glycoside poisoning. Br J Clin Pharmacol. 2016;81(3):488-495. https://doi.org/10.1111/bcp.12814
38. Bismuth C., Gaultier M., Conso F., Efthymiou M.L. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-162. https://doi.org/10.3109/15563657308990513
39. Dasgupta A., Datta P. Rapid detection of oleander poisoning using digoxin immunoassays: comparison of five assays. Ther Drug Monit. 2004;26(6):658-663. https://doi.org/10.1097/00007691-200412000-00012
40. Min J.S., Kim J., Kim J.H., Kim D., Zheng Y.F., Park J.E., Lee W., Bae S.K. Quantitative determination of arenobufagin in rat plasma by ultra fast liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal. 2013;15(939):86-91. https://doi.org/10.1016/j.jpba.2017.08.048
41. Omidfar K., Kia S., Kashanian S., Paknejad M., Besharatie A., Kashanian S., Larijani B. Colloidal nanogoldbased immunochromatographic strip test for the detection of digoxin toxicity. Applied Biochemistry and Biotechnology. 2010;160(3):843-855. https://doi.org/10.1007/s12010-009-8535-x
42. Payne V.W., Secter R.A., Noback R.K. Use of colestipol in a patient with digoxin intoxication. Drug Intell Clin Pharm. 1981;15(11):902-903. https://doi.org/10.1177/106002808101501109
43. Caldwell J.H., Greenberger N.J. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. J Clin Invest. 1971;50(12):2626-2637. https://doi.org/10.1172/JCI106763
44. Gilfrich H.J., Okonek S., Manns M., Schuster C.J. Digoxin and digitoxin elimination in man by charcoal hemoperfusion. Klin Wochenschr. 1978;56 (23):1179-1183. https://doi.org/10.1007/bf01476862
45. Mowry J.B, Burdmann A.E., Anseeuw K., Ayoub P., Ghannoum M., Hoffman R.S., Lavergne V., Nolin T.D., Gosselin S., the EXTRIP Workgroup. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup, Clinical Toxicology. 2016;54(2):103-114. https://doi.org/10.3109/15563650.2015.1118488
46. Roberts D.M., Buckley N. Antidotes for acute cardenolide (cardiac glycoside) poisoning. Cochrane Database of Systematic Reviews. 2006; 4 Art. No.: CD005490. https://doi.org/10.1002/14651858.CD005490.pub2
47. de Silva H.A., Fonseka M.M., Pathmeswaran A., Alahakone D.G., Ratnatilake G.A., Gunatilake S.B., Ranasinha C.D., Lalloo D.G., Aronson J.K., de Silva H.J. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet. 2003;361(9373):1935-1938. https://doi.org/10.1016/s0140-6736(03)13581-7
48. Eddleston M., Juszczak E., Buckley N.A., Senarathna L., Mohamed F., Sheriff M.H.S., Warrell D.A. Randomised controlled trial of routine single or multiple dose superactivated charcoal for self-poisoning in a region with high mortality. Clinical Toxicology 2005;43:442-443.
49. Eddleston M., Rajapakse S., Rajakanthan S., Sjöström L., Santharaj W., Thenabadu P.N., Sheriff M.H.R., Warrell D.A. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet. 2000;355(9208):967-972. https://doi.org/10.1016/s0140-6736(00)90014-x
50. Antman E.M., Wenger T.L., Butler V.P. Jr., Haber E., Smith T.W. Treatment of 150 cases of lifethreatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-1752. https://doi.org/10.1161/01.cir.81.6.1744
51. Felicilda-Reynaldo R.F. Cardiac glycosides, digoxin toxicity, and the antidote. Medsurg Nurs. 2013;22(4): 258-261.
52. Hickey A.R., Wenger T.L., Carpenter V.P., Tilson H.H., Hlatky M.A., Furberg C.D., Kirkpatrick C.H., Strauss H.C., Smith T.W. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. Journal of the American College of Cardiology. 1991;17(3): 590-598. https://doi.org/10.1016/s0735-1097(10)80170-6
53. Ujhelyi M.R., Robert S. Pharmacokinetic aspects of digoxin-specific fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28(6):483-493. https://doi.org/10.2165/00003088-199528060-00006
54. Hursting M.J., Raisys V.A., Opheim K.E., Bell J.L., Trobaugh G.B., Smith T.W. Determination of free digoxin concentrations in serum for monitoring Fab treatment of digoxin overdose. Clin Chem. 1987;33(9):1652-1655.
55. FDA-approved labeling information: Digoxin Immune Fab (Ovine) (DigiFab), 2001 (revised in 2018). https://www.fda.gov/media/74693/
56. Hoffman R.S., Howland M., Levin N.A., Nelson L.S., Goldfrank L.R. Goldfrank’s Toxicologic Emergencies, 10th edition. New York: McGraw-Hill Education, 2014:1904. ISSN 978-0071801843
57. Bracken L.M., Chan B.S.H., Buckley N.A. Physiologically based pharmacokinetic modelling of acute digoxin toxicity and the effect of digoxinspecific antibody fragments. Clinical Toxicology. 2019;57(2):117-124. https://doi.org/10.1080/15563650.2018.1503288
58. Wessler D.J., Grip L.T., Mendell J., Giugliano R.P. The P-Glycoprotein Transport System and Cardiovascular Drugs. JACC. 2013;61(25):2495-2502. https://doi.org/10.1016/j.jacc.2013.02.058
59. Schaffer S., Kim H.W. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018;26(3):225-241. https://doi.org/10.4062/biomolther.2017.251
60. Ma H., Jiang, J., Zhang J., Zhou J., Ding A., Lv G., Duan, J. Protective effect of taurine on cardiotoxicity of the bufadienolides derived from toad (Bufo bufo gargarizans Canto) venom in guinea-pigs in vivo and in vitro. Toxicology Mechanisms and Methods. 2011:22(1):1–8. https://doi.org/10.3109/15376516.2011.583295
61. Satoh H. Cardiac actions of taurine as a modulator of the ion channels. Adv Exp Med Biol. 1998;442:121-128. https://doi.org/10.1007/978-1-4899-0117-0_16
62. Pincus M. Management of digoxin toxicity. Aust Prescr. 2016;39(1):18–20. https://doi.org/10.18773/austprescr.2016.006
63. Shulkin A.V., Yakusheva E.N., Popova N.M. The role of P-glycoprotein in rational pharmacotherapy in cardiology. Ration Pharmacother Cardiol. 2013;9(6):701-707. https://doi.org/10.20996/1819-6446-2013-9-6- 701-707
64. Nola G.T., Pope S., Harrison D.C. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79(4):499-507. https://doi.org/10.1016/0002-8703(70)90255-3
65. Levine M., Nikkanen H., Pallin D.J. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41-46. https://doi.org/10.1016/j.jemermed.2008.09.027
66. Van Deusen S.K., Birkhahn R.H., Gaeta T.J. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Clin Toxicol. 2003;41(4):377-379. https://doi.org/10.1081/clt-120022006
67. Hack J.B., Woody J.H., Lewis D.E., Brewer K., Meggs W.J. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol. 2004;42(4):337-342. https://doi.org/10.1081/clt-120039538
68. Oubaassine R., Bilbault P., Roegel J.C., Alexandre E., Sigrist S., Lavaux T., Jaeger A., Pinget M., Kessler L. Cardio protective effect of glucose-insulin infusion on acute digoxin toxicity in rat. Toxicology. 2006;224(3): 238-243. https://doi.org/10.1016/j.tox.2006.04.035
Рецензия
Для цитирования:
Шперлинг М.И., Кручинин Е.Г., Гоголевский А.С. Фармакологические аспекты лечения острой гликозидной интоксикации. Вестник медицинского института «РЕАВИЗ». Реабилитация, Врач и Здоровье. 2021;(4):120-134. https://doi.org/10.20340/vmi-rvz.2021.4.CLIN.1
For citation:
Sperling M.I., Kruchinin E.G., Gogolevsky A.S. Pharmacological aspects of acute treatment glycoside intoxication. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2021;(4):120-134. (In Russ.) https://doi.org/10.20340/vmi-rvz.2021.4.CLIN.1
Просмотров:
694
Послать статью по эл. почте 